The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2016
year mood -0.11 · -0.28 to +0.10 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan Feb -0.28 Mar Apr May Jun Jul Aug Sep Oct Nov +0.10 Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
-0.10-0.28-0.10-0.20-0.10-0.10-0.10-0.14-0.20-0.20+0.10+0.10

Healthcare sentiment is neutral this month, weighed down primarily by the sharp decline in Valeant’s shares following a guidance cut and mounting credibility concerns, which rattled investor confidence in high-multiple names. While broader market conditions remain stable, the sector’s tone is tempered by scrutiny on pricing practices and corporate transparency, highlighted by Valeant’s struggles. No other major sector-wide catalysts emerged to shift the overall balance.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2016
Feb
Valeant shares plunge 50% after guidance cut and credibility concerns theglobeandmail.com →

Valeant Pharmaceuticals slashed its 2016 sales and earnings forecasts, leading to a 50% stock drop as CEO Michael Pearson sought to restore trust amid accounting scrutiny and regulatory probes. The company plans asset sales, debt reduction, and pricing stability, but faces investor skepticism over past practices and opaque finances. Market implications include prolonged investor caution and delayed recovery prospects amid $31-billion debt burden.

Aug
Mylan faces backlash over 500% EpiPen price hike cbsnews.com →

Mylan came under intense public and congressional scrutiny for raising EpiPen prices by nearly 500% from 2009 to 2016, sparking outrage over drug affordability. CEO Heather Bresch defended the hikes, citing investments in awareness and access, while blaming the complex supply chain and pointing to $334 of the $608 price going to intermediaries like PBMs. The controversy highlights systemic issues in drug pricing, with market implications for transparency, regulation, and competition in the pharmaceutical industry.